PRTK

Omadacycline (Nuzyra)

Acute bacterial skin and skin structure infections (ABSSSI) - IV Only

Stage (next event)

Expected Date

Approved

Q1 '20

Catalyst Info & Data Links

TITLE: Omadacycline (Nuzyra) for Acute bacterial skin and skin structure infections (ABSSSI) Approved

  • Approved

WHAT IS THE NEXT CATALYST EVENT?

  • Q4 '20 sales

WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • Q1' 20 (2/21)

Mechanism of Action

DV

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See what the community is saying - click to see full post

NBRV down 16.6% Today - Market Remains Tough on Companies Developing New Antibiotics

Paratek Pharmaceuticals Announces Positive Data for Omadacycline in Community-Acquired Bacterial Pne

AMP Announces Q2 Picks

AMP Buys Shares in Paratek Pharmaceuticals (PRTK) in Hypothetical Fund

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon